| Size | Price | |
|---|---|---|
| 100mg | ||
| 500mg | ||
| Other Sizes |
| Molecular Formula |
C20H25NO6
|
|---|---|
| Molecular Weight |
375.42
|
| Exact Mass |
375.168
|
| CAS # |
156604-79-4
|
| Related CAS # |
Ketoprofen;22071-15-4;S-(+)-Ketoprofen;22161-81-5;Dexketoprofen-d3 (trometamol);2747914-78-7
|
| PubChem CID |
6918332
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
431.3ºC at 760 mmHg
|
| Flash Point |
228.8ºC
|
| Vapour Pressure |
3.32E-08mmHg at 25°C
|
| LogP |
1.466
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O.C(C(CO)(CO)N)O
|
| InChi Key |
QUZMDHVOUNDEKW-MERQFXBCSA-N
|
| InChi Code |
InChI=1S/C16H14O3.C4H11NO3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12;5-4(1-6,2-7)3-8/h2-11H,1H3,(H,18,19);6-8H,1-3,5H2/t11-;/m0./s1
|
| Chemical Name |
2-amino-2-(hydroxymethyl)propane-1,3-diol;(2S)-2-(3-benzoylphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6637 mL | 13.3184 mL | 26.6368 mL | |
| 5 mM | 0.5327 mL | 2.6637 mL | 5.3274 mL | |
| 10 mM | 0.2664 mL | 1.3318 mL | 2.6637 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07386288
Conditions:Renal ColicLink: https://clinicaltrials.gov/ct2/show/NCT07176572
Conditions:Renal ColicLink: https://clinicaltrials.gov/ct2/show/NCT06916234
Conditions:Acute Dental Pain
Title:Approach to Ankle Sprains in the Emergency Department
Status:Completed
updateDate:2024-08-20
Ctid:NCT06563271
Link: https://clinicaltrials.gov/ct2/show/NCT06563271
Conditions:Ankle SprainsLink: https://clinicaltrials.gov/ct2/show/NCT06558916
Conditions:Analgesia|Renal ColicLink: https://clinicaltrials.gov/ct2/show/NCT04252521
Conditions:MigraineLink: https://clinicaltrials.gov/ct2/show/NCT05125796
Conditions:Scorpion StingsLink: https://clinicaltrials.gov/ct2/show/NCT05529290
Conditions:Temporomandibular DisorderLink: https://clinicaltrials.gov/ct2/show/NCT04213287
Conditions:IPACK Block Multimodal Analgesia|Postoperative NRS ScoresLink: https://clinicaltrials.gov/ct2/show/NCT04200885
Conditions:Third Molar SurgeryLink: https://clinicaltrials.gov/ct2/show/NCT04161690
Conditions:Postoperative Pain|AnalgesiaLink: https://clinicaltrials.gov/ct2/show/NCT03697746
Conditions:DysmenorrheaLink: https://clinicaltrials.gov/ct2/show/NCT03420911
Conditions:Pain, Acute|AnxietyLink: https://clinicaltrials.gov/ct2/show/NCT03107338
Conditions:Acute PainLink: https://clinicaltrials.gov/ct2/show/NCT02380001
Conditions:Postoperative PainLink: https://clinicaltrials.gov/ct2/show/NCT02160236
Conditions:Postoperative PainLink: https://clinicaltrials.gov/ct2/show/NCT02086097
Conditions:Irreversible PulpitisLink: https://clinicaltrials.gov/ct2/show/NCT02092012
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT01947205
Conditions:Curettage|Analgesia|Paracervical Block|ParacetamolLink: https://clinicaltrials.gov/ct2/show/NCT01307020
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT01558622
Conditions:Laparoscopic Nissen FundoplicationLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004545-32
Condition:Treatment of moderate to severe acute pain following abdominal hysterectomyLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022798-32
Condition:Severe pain following impacted third mandibular molar tooth extractionLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006182-32
Condition:Postoperative pain in burned patients with a burn excision area between 2 and 12 % of total body surface area.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001789-42
Condition:Patients who underwent ambulatory surgery consisting in unilateral inguinal mesh hernioplastyLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001373-26
Condition:elective orthopedic surgery (hip arthroplasty)Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
